Patents by Inventor John E. Smart
John E. Smart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7208483Abstract: Polymeric delivery agents, delivery agent compounds and compositions comprising them which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: May 28, 2003Date of Patent: April 24, 2007Assignee: Emisphere Technologies, Inc.Inventors: Sam J. Milstein, Eugene N. Barantsevitch, Nai Fang Wang, Jun Liao, John E. Smart, Richard D. Conticello, Raphael M. Ottenbrite
-
Patent number: 7129274Abstract: Phenoxy carboxylic acid compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: November 6, 2000Date of Patent: October 31, 2006Assignee: Emisphere Technologies Inc.Inventors: Andrea Leone-Bay, Kelly Kraft, Destardi Moye-Sherman, David Gschneidner, Maria A. P. Boyd, Puchun Liu, Pingwah Tang, Jun Liao, John J. Freeman, Jr., John E. Smart
-
Patent number: 7060680Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: GrantFiled: January 15, 2002Date of Patent: June 13, 2006Assignee: Curis, Inc.Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang, Engin Ozkaynak, John E. Smart
-
Patent number: 7056882Abstract: The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.Type: GrantFiled: September 13, 2001Date of Patent: June 6, 2006Assignee: Curis, Inc.Inventors: Thangavel Kuberasampath, Charles M. Cohen, Herrmann Oppermann, Engin Ozkaynak, David C. Rueger, John E. Smart, Roy H. L. Pang
-
Patent number: 6949505Abstract: Disclosed are methods and compositions for maintaining neural pathways in a mammal including: enhancing survival of neurons at risk of dying; inducing cellular repair of damaged neurons and neural pathways; stimulating neurons to maintain their differentiated phenotype; and promoting dendritic outgrowth, including maintaining dendritic arbors and regenerating dendritic architecture. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.Type: GrantFiled: August 18, 1994Date of Patent: September 27, 2005Assignees: Curis, Inc., The Research Foundation of State University of New YorkInventors: David C. Rueger, Kuber T. Sampath, John E. Smart, Hermann Oppermann, Engin Ozkaynak, Charles M. Cohen, Dennis Higgins
-
Patent number: 6693073Abstract: The present invention provides methods for administering an active agent to an animal in need of the agent by the pulmonary route. This method comprises administering via the pulmonary route, a composition comprising (a) an active agent and (b)(i) an acylated amino acid, (ii) a sulfonated amino acid, or (iii) a combination of (i) and (ii). Administration of the compositions of the present invention provide improved pulmonary delivery and greater bioavailability of the active agent than administration of the active agent alone. As a result, lesser amounts of the active agent may be administered to obtain a desired result when contained in the composition of the present invention than when administered alone.Type: GrantFiled: June 14, 2002Date of Patent: February 17, 2004Assignee: Emisphere Technologies, Inc.Inventors: Sam J. Milstein, John E. Smart, Donald J. Sarubbi, Monica Leipold, Elizabeth Flanders, Doris O'Toole, Andrea Leone-Bay, David Gschneidner
-
Publication number: 20030232085Abstract: Polymeric delivery agents, delivery agent compounds and compositions comprising them which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: ApplicationFiled: May 28, 2003Publication date: December 18, 2003Applicants: Emisphere Technologies, Inc., Virginia Commonwealth UniversityInventors: Sam J. Milstein, Eugene N. Barantsevitch, Nai Fang Wang, Jun Liao, John E. Smart, Richard D. Conticello, Raphael M. Ottenbrite
-
Publication number: 20030224979Abstract: The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.Type: ApplicationFiled: September 13, 2001Publication date: December 4, 2003Inventors: Thangavel Kuberasampath, Charles M. Cohen, Herrmann Oppermann, Engin Ozkaynak, David C. Rueger, John E. Smart, Roy H.L. Pang
-
Patent number: 6627228Abstract: Polymeric delivery agents, delivery agent compounds and compositions comprising them which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: October 9, 2001Date of Patent: September 30, 2003Assignee: Emisphere Technologies, Inc.Inventors: Sam J. Milstein, Eugene N. Barantsevitch, Nai Fang Wang, Jun Liao, John E. Smart, Richard D. Conticello, Raphael M. Ottenbrite
-
Publication number: 20030176667Abstract: Disclosed are a family of single-chain polypeptide constructs designed to agonize or mimic members of the TGF-&bgr; superfamily by binding to a cell surface receptor complementary to the superfamily member. The single-chain constructs of the invention called “morphons” contain in a single biologically active subunit interacting finger and heel regions which together define a tertiary protein structure complimentary to the ligand binding surface of a receptor that binds a TGF-&bgr; superfamily member. Also disclosed are truncated versions of the morphon constructs. Methods are disclosed for making and using single-chain morphons that have binding affinity for predetermined receptors of the TGF-&bgr; superfamily.Type: ApplicationFiled: June 28, 2002Publication date: September 18, 2003Applicant: Stryker CorporationInventors: Peter C. Keck, John E. Smart
-
Publication number: 20030125230Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: ApplicationFiled: January 15, 2002Publication date: July 3, 2003Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H.L. Pang, Engin Ozkaynak, John E. Smart
-
Publication number: 20030072740Abstract: The present invention provides methods for administering an active agent to an animal in need of the agent by the pulmonary route. This method comprises administering via the pulmonary route, a composition comprising (a) an active agent and (b)(i) an acylated amino acid, (ii) a sulfonated amino acid, or (iii) a combination of (i) and (ii). Administration of the compositions of the present invention provide improved pulmonary delivery and greater bioavailability of the active agent than administration of the active agent alone. As a result, lesser amounts of the active agent may be administered to obtain a desired result when contained in the composition of the present invention than when administered alone.Type: ApplicationFiled: June 14, 2002Publication date: April 17, 2003Applicant: Emisphere Technologies, Inc.Inventors: Sam J. Milstein, John E. Smart, Donald J. Sarubbi, Monica Leipold, Elizabeth Flanders, Doris O'Toole, Andrea Leone-Bay, David Gschneidner
-
Patent number: 6479643Abstract: Disclosed are a family of single-chain polypeptide constructs designed to agonize or mimic members of the TGF-&bgr; superfamily by binding to a cell surface receptor complementary to the superfamily member. The single-chain constructs of the invention called “morphons” contain in a single biologically active subunit interacting finger and heel regions which together define a tertiary protein structure complimentary to the ligand binding surface of a receptor that binds a TGF-&bgr; superfamily member . Also disclosed are truncated versions of the morphon constructs. Methods are disclosed for making and using single-chain morphons that have binding affinity for predetermined receptors of the TGF-&bgr; superfamily.Type: GrantFiled: February 2, 2000Date of Patent: November 12, 2002Assignee: Stryker CorporationInventors: Peter C. Keck, John E. Smart
-
Patent number: 6440929Abstract: The present invention relates to pulmonary delivery of active agents. Acylated or sufonated amino acids are used as carriers to facilitate pulmonary delivery of active agents to a target.Type: GrantFiled: April 26, 2001Date of Patent: August 27, 2002Assignee: Emisphere Technologies, Inc.Inventors: Sam J. Milstein, John E. Smart, Donald J. Sarubbi, Monica Leipold, Elizabeth Flanders, Doris O'Toole, Andrea Leone-Bay, David Gschneidner
-
Patent number: 6399569Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: GrantFiled: June 5, 1995Date of Patent: June 4, 2002Assignee: Curis, Inc.Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang, Engin Ozkaynak, John E. Smart
-
Patent number: 6333312Abstract: The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.Type: GrantFiled: October 13, 1998Date of Patent: December 25, 2001Assignee: Curis, Inc.Inventors: Thangavel Kuberasampath, Charles M. Cohen, Herrmann Oppermann, Engin Ozkaynak, David C. Rueger, John E. Smart, Roy H. L. Pang
-
Patent number: 6184531Abstract: An improved apparatus for collecting and analyzing an airborne particulate radionuclide having a filter mounted in a housing, the housing having an air inlet upstream of the filter and an air outlet downstream of the filter, wherein an air stream flows therethrough. The air inlet receives the air stream, the filter collects the airborne particulate radionuclide and permits a filtered air stream to pass through the air outlet. The improvement which permits real time counting is a gamma detecting germanium diode mounted downstream of the filter in the filtered air stream. The gamma detecting germanium diode is spaced apart from a downstream side of the filter a minimum distance for a substantially maximum counting detection while permitting substantially free air flow through the filter and uniform particulate radionuclide deposition on the filter.Type: GrantFiled: April 17, 1998Date of Patent: February 6, 2001Assignee: Battelle Memorial InstituteInventors: John E. Smart, Richard W. Perkins
-
Patent number: 6093547Abstract: Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptor; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods for identifying novel morphogen receptors and their encoding DNAs; (4) methods for identifying compounds capable of modulating endogenous morphogen receptor levels; and (5) methods for identifying morphogen receptor binding analogs useful in the design of morphogen agonists and antagonists for therapeutic, diagnostic and experimental uses.Type: GrantFiled: June 2, 1995Date of Patent: July 25, 2000Assignee: Creative Biomolecules, Inc.Inventors: Donald F. Jin, Hermann Oppermann, Thangavel Kuberasampath, John E. Smart
-
Patent number: 6090776Abstract: The present invention is directed to methods and compositions for enhancing viability of organs and living tissues to be transplanted in a mammal. The methods and compositions provide a therapeutically effective concentration of a morphogen or morphogen-stimulating agent to the tissue or organ to be transplanted, sufficient to substantially protect the tissue or organ from tissue damage.Type: GrantFiled: June 7, 1995Date of Patent: July 18, 2000Assignee: Creative Bio Molecules, Inc.Inventors: Thangavel Kuberasampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger, Charles M. Cohen, John E. Smart
-
Patent number: 6077823Abstract: The present invention is directed to methods and compositions for alleviating tissue destructive effects associated with the inflammatory response to tissue injury in a mammal. The methods and compositions include administering a therapeutically effective concentration of a morphogen or morphogen-stimulating agent sufficient to alleviate immune cell-mediated tissue destruction.Type: GrantFiled: May 22, 1995Date of Patent: June 20, 2000Assignee: Creative BioMolecules, Inc.Inventors: Thangavel Kuberasampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger, Charles M. Cohen, John E. Smart